11/13
07:23 am
syre
Rating for SYRE
Medium
Report
Rating for SYRE
11/13
07:23 am
syre
Rating for SYRE
Medium
Report
Rating for SYRE
11/8
10:05 pm
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
Low
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
11/8
10:05 pm
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
Low
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
10/25
03:31 pm
syre
Rating for SYRE
Low
Report
Rating for SYRE
10/25
03:31 pm
syre
Rating for SYRE
Low
Report
Rating for SYRE
9/4
11:24 am
syre
Rating for SYRE
Low
Report
Rating for SYRE
9/4
11:24 am
syre
Rating for SYRE
Low
Report
Rating for SYRE
9/4
08:37 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $45.00 price target on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $45.00 price target on the stock.
9/4
08:37 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $45.00 price target on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $45.00 price target on the stock.
9/3
04:34 pm
syre
Spyre Therapeutics initiated with bullish view at Wedbush
Medium
Report
Spyre Therapeutics initiated with bullish view at Wedbush
9/3
04:34 pm
syre
Spyre Therapeutics initiated with bullish view at Wedbush
Medium
Report
Spyre Therapeutics initiated with bullish view at Wedbush